Just read this thread, a bit confusing, but it sounds like everyone has it worked out now :)
I must admit, I initially misunderstood the figures, because of the following footer:"realistically addressible market means the estimated portion of the market we can directly access with Mix&Go, not total market size which is much higher and provided in most cases as a point of reference.""Realistically addressable market" implies to me "the market that can realistically utilise Mix&Go and gain some benefit", rather than the "value attributable to ADO for 100% take up."
I imagine the actual market size that Mix&Go can provide benefit isn't 100% (but don't know what it is?), particularly considering the wording of the eBioscience agreement that points out Mix&Go won't be used across the whole product range, just the "appropriate" products.
Is anyone able to shed any light on this? ie: Is Mix&Go really able to benefit every single product in the $10.5b IVD market?
Add to My Watchlist
What is My Watchlist?
